

# Author Index

(Vol. 24 No. 1-3 January-December 2007)

<b>A</b>		<b>J</b>		<b>S</b>	
Annanon N	104	Jirajariyavej S	105	Santanirand P	143
Apisarnthanarak A	47,75,95, 151, 173	Jongjirawisan Y	103	Sathapatayavongs B	163
Arora DR	13	<b>K</b>		Sekaran SD	19
Arseculeratne S	133	Krajaejun T	163	Senanayake S	133
Arseculeratne SN	125	Kulwichit W	102	Senaratne T	133
Atamasirikul K	103	Kumar V	29,83	Shamma M	55
<b>C</b>		Kumari N	19	Sharma A	13
Chaikittisuk N	107	Kundra S	13	Sharma M	29
Chaiprasert A	163	<b>L</b>		Srifuengfung S	1,117
Chaudhary U	29,55,83	Leepethacharat K	63	Srimuang S	163
Chayakul P	49	<b>M</b>		Suankratay C	101,105
Chayakul V	49	Manosuthi W	89	Subramaniam G	19
Chiangjong W	117	Moniri R	7	Sungkanuparph S	35,89,103, 143,173
Chokephaibulkit K	1	Mootsikapun P	33,43,45,87, 99,149,171	<b>T</b>	
<b>E</b>		Mosayebi Z	7	Tangkosalakul T	143
Edussuriya K	133	Movahedian AH	7	Tribuddharat C	1,117
Eriyagama NB	125	Mundy LM	151	<b>U</b>	
<b>G</b>		Munsrichoom A	107	Ungulkraiwit P	103
Gautam V	13	<b>N</b>		<b>W</b>	
Goel N	29,83	Navaratnam P	19	Wijenayake P	133
Griwan MS	29	<b>O</b>		Wongnak K	143
Griwan MS	83	Oberdorfer P	63	<b>Y</b>	
Gupta N	13	<b>P</b>		Yadav A	55
<b>H</b>		Pongkumpai M	101		
Hongmanee P	143	Poonwan N	1		
Hortiwakul R	49	Putcharoen O	102		
<b>I</b>					
Ingviya N	49				

# Subject Index

(Vol. 24 No. 1-3 January-December 2007)

<b>A</b>			Enterococcus	55	Nitrofurantoin	49	
<i>Acinetobacter baumannii</i> , pediatric patients, infection	63	ESBLs, antibiotic susceptibility, prevalence	107	Nocardia, respiratory tract infection	1		
Aminoglycoside resistance, susceptibility	55	<i>Escherichia coli</i>	13,75	Non-tuberculous mycobacteria	143		
Antibiotic resistance	19	Extended-spectrum beta-lactamase (ESBL)	117	<b>O</b>			
Antimicrobial resistance	49	Extended-spectrum $\beta$ -lactamase (ESBL) producing		Ocular rhinosporidiosis	133		
Antimicrobial susceptibility	13	<i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i>	107	<b>P</b>			
Antimicrobial susceptibility profile	49	<b>F</b>			Phenotype	117	
Antiretroviral therapy	35	Fluoroquinolone resistance	19	pmrA	19		
<b>B</b>			Fosfomycin	49	<b>R</b>		
Biocide-sensitivity	125	<b>G</b>			<i>Rhinosporidium seeberi</i>	125	
<b>C</b>			Genotype	117	<b>S</b>		
Carbapenems	47	<b>H</b>			Species distribution	49	
Case-control, Extended- spectrum beta-lactamases	75	HIV	35,89	Staphyloma formation	133		
<i>Clostridium difficile</i>	151	Hypervirulence	151	<i>Streptococcus pneumoniae</i>	19		
Colorectal surgery, developing countries	47	<b>I</b>			Surgical prophylaxis	47	
Community-onset extended- spectrum beta-lactamase- producing <i>Escherichia coli</i>	75	Imipenem	49	<b>T</b>			
<b>D</b>			<b>K</b>			Tenofovir	35
Dapsone therapy	133	<i>Klebsiella pneumoniae</i>			Tenosynovitis	143	
Diarrhea	151	<b>M</b>			<b>U</b>		
<b>E</b>			Methicillin-resistant <i>Staphylococcus aureus</i> , burn, burn care unit, India	29	Urinary tract infection, uropathogen	13	
Efavirenz	89	MTT-reduction test	125	Urinary tract infections, newborn, drug resistance	7		
Efflux pump	19	<i>Mycobacterium kansasii</i>	143	<b>V</b>			
Emerging infectious diseases, treatment	151	<b>N</b>			Vancomycin	49	
Endospores	125	Nevirapine, rash	89	Vancomycin-resistant enterococci	55		
Enterococci	49						